/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Sep 11, 2026

CML treatment goals have shifted from survival to tolerability & treatment-free remission, with asciminib showing superior efficacy & safety.

Asciminib's Key Advantage in CML is Driven by Tolerability, Not Just Efficacy

While the new CML drug Asciminib demonstrates better efficacy, its most significant advantage is superior tolerability. Clinical trial data shows it causes significantly fewer treatment discontinuations due to adverse events compared to both Imatinib and second-generation TKIs, improving patient adherence and quality of life.

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) thumbnail

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos·2 months ago

CML Specialists Transplant High-Risk Patients Too Late Despite Predictive Markers

While tyrosine kinase inhibitors (TKIs) reduced overall CML transplants, a dangerous trend has emerged. Clinicians are waiting too long to transplant high-risk patients, often until after they reach an advanced disease state, which significantly worsens outcomes compared to an early transplant in the chronic phase.

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) thumbnail

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos·2 months ago

ASXL1 Mutation Undermines Asciminib's Efficacy, Requiring Combination Therapy

The ASXL1 mutation, found in 11-15% of newly diagnosed CML patients, negates the efficacy benefit of the highly specific BCR-ABL inhibitor Asciminib. This suggests that for this patient subset, Asciminib monotherapy is insufficient, and combination treatments are likely necessary to overcome this form of molecular resistance.

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) thumbnail

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos·2 months ago

CML Treatment Goals Now Vary by Patient Age and Treatment Duration

The primary goal in Chronic Myeloid Leukemia (CML) has evolved from survival to tolerability and treatment-free remission. These goals are not uniform; younger patients prioritize stopping treatment to start families, while long-term patients increasingly value better tolerability over marginal efficacy gains.

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) thumbnail

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos·2 months ago

Weekend Drug Holidays Mitigate Dasatinib's Side Effects Without Sacrificing Efficacy

To manage Dasatinib's common side effect of pleural effusions, a randomized study showed that skipping doses on weekends is superior to dose reduction. This strategy leverages the drug's short half-life, maintaining peak levels for efficacy while providing a break from off-target effects that cause toxicity.

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) thumbnail

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos·2 months ago

Interferon Fails to Improve CML Outcomes; Its Sole Indication Is Now Pregnancy

Despite extensive investigation, adding interferon to tyrosine kinase inhibitors (TKIs) does not significantly improve rates of deep molecular response or treatment-free remission in CML. Based on consistent data, its use is no longer recommended except as a bridging therapy for pregnant patients.

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) thumbnail

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)

Research To Practice | Oncology Videos·2 months ago